Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience

Patnayak, Rashmi; Jena, Amitabh; Rukmangadha, Nandyala; Chowhan, Amit Kumar; Sambasivaiah, K; Phaneendra, Bobbidi Venkata; Reddy, Munish

doi:10.4103/0971-5851.158844

Cited by 44 publications

(61 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,58 The connection of PR positive and a slower histological progress in breast cancer observed in this study might also be a result of a negative association between PR and Her-2 positive in breast cancers 56 caused by the loss of PR protein due to Her-2 overexpression through the PI3K/Akt signaling pathway. 59 Relationship of Her-2, PR, ER, Ki-67 and p53 in signaling transduction pathways In this study, it was found that Her-2 overexpression was negatively connected with PR and ER expression and positively connected with Ki-67 positive and p53 positive, which was consistent with previous reports 30,32,37,44,46,49,53,59,60 This suggests that there might be some relationship among Her-2 and these genes in signal transduction pathways. Through MAPK and PI3K signaling pathways, Her-2 prevents apoptosis and promotes cell proliferation.…”

Section: Discussionsupporting

confidence: 92%

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

Zhang

et al. 2017

Bioengineered

View full text Add to dashboard Cite

The objective was to study the relationship among Her-2, Ki-67, p53 expression and the clinicopathologic characteristics of breast cancer in the patients of northern China. Expression of Her-2, Ki-67, p53 and clinical characteristics of 260 breast cancer patients were retrospectively studied. Her-2 overexpression led to higher incidence rates of infiltrating ductal carcinoma and axillary lymph node metastasis, bigger diameters of the primary tumors, later pTNM staging, and a lower incidence rate of ductal carcinoma in situ (p < 0.05). High expression of ER and PR led to fewer patients classified histologically in higher grade (p D 0.001), while high expression of Ki-67 and p53 caused more patients classified histologically in higher grade (p D 0.001). In patients histologically classified in grade 1 and 2, the expression of Ki-67 and p53 was significantly (p D 0.001) higher, and the expression of ER and PR was significantly lower, in Her-2 positive patients than Her-2 negative patients. Breast cancer with Her-2 overexpression was more likely to recur and metastasize than Her-2 negative breast cancer. Higher coincidence of high expression of p53 and Ki-67 with Her-2 overexpression and more progressed tumors suggested that in addition to p53, Ki-67 might also be a prognostic biomarker of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 92%

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

Zhang

et al. 2017

Bioengineered

View full text Add to dashboard Cite

show abstract

“…Her-2/Neu status was positive in only 6 cases (12.5%). Study done by Onitilo AA et al 28 and Patnayak R et al 29 showed somewhat similar results. We included early (Stage I and II) and locally advanced (Stage III) breast cancers in this study.…”

Section: Discussionsupporting

confidence: 59%

Clinico-Pathological Study: 48 Cases of Carcinoma Breast at Tertiary Care Centre in Rural Area

Nikhade¹,

Subhedar²,

Shelke³

et al. 2016

jemds

View full text Add to dashboard Cite

BACKGROUND Carcinoma breast is the most common site of specific cancer in women. In India, the incidence of breast cancer is increasing rapidly to be number one cancer, now cervical cancer became second in place. Breast lump is the commonest symptom and once clinically apparent carcinoma tends to spread distantly which greatly varies from patient to patient and is characteristic of heterogeneity of the disease.The aim of the study is to study carcinoma breast with respect to various risk factors, age distribution, clinical presentation and histopathological findings. MATERIALS AND METHODSThis is a hospital-based prospective observational study and data used was obtained from 48 cases that were evaluated at our institute from September 2013 to August 2015 and diagnosed to have carcinoma breast. RESULTSAll the patients were females with average age of 51 years. Average age of menarche was 13 years. with almost equal proportions of pre-and post-menopausal women. Only one patient was nulliparous, rest of all the patients breast fed their children; 8.3% of the patients had a family history of disease and they all had earlier age of presentation. Duration of symptoms was more than 6 months in 43.8% cases, which reflects negligence of patients. Lump in breast was a presenting complaint in all the patients (100%) followed by nipple retraction (33.3%); 14.6% of patients had stage I disease, 39.6% had stage II disease and 45.8% had stage III disease; 81.3% of cases were of infiltrating ductal carcinoma; 60.4% of patient's samples were ER positive, while 52.1% were PR positive; 83.2% of cases were discharged without any complications. CONCLUSIONFNAC was highly effective in diagnosing malignancy. Infiltrating ductal carcinoma was the most common histopathological type. A significant proportion of patients were hormone receptor positive depicting the role of hormonal therapy in the management. Early breast carcinomas are well treated with modified radical mastectomy with a need of chemoradiation in selected cases. The management of Locally Advanced Breast Carcinoma requires complex multidisciplinary approach. Raising awareness about the screening procedures and treatment of breast cancer can help reducing mortality. HOW TO CITE THIS ARTICLE:Nikhade PW, Subhedar AD, Shelke SL, et al. Clinico-pathological study: 48 cases of carcinoma breast at tertiary care centre in rural area.

show abstract

“…18 Another study from one tertiary care centre in India revealed 22.7% triple negative cases. 19 And one large study by Sandhu et al by combining the data from seventeen studies from India involving 7,237 breast cancer patients found 31% incidence of TNBC. 20 This finding is also alarming because the targeted therapy to ER, PR, HER2 receptor are of no use in TNBC causing lower disease free survival and overall survival.…”

Section: Discussionmentioning

confidence: 99%

Study of correlation of ER, PR, HER2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor

Shukla

Singh

Shukla

et al. 2018

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: The receptor status of breast cancer, including ER, PR and HER 2, play a crucial role in the development of treatment plan of breast cancer. Clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well established, added value of PR is less defined. This study aim to know the demography of breast cancer and to document the status of ER, PR and HER 2 status in the north Indian population, as catered by single tertiary care hospital in Lucknow, Uttar Pradesh.Methods: All the patients of breast cancers where surgery or core biopsy was performed for invasive breast carcinoma followed by evaluation of ER, PR and HER 2 status were included in the study from January 2014 to June 2018. Cases were analyzed retrospectively for documentation of ER, PR and HER2 status, using American society of Clinical Oncology/College of American Pathologists (ASCO/CAP) interpretation guidelines.Results: 112 patients were included in the study with mean age of 53.70±12.47. Most common histological type was invasive carcinoma of no special type. 43.75% cases were ER+/PR+, 5.35% were ER+/PR-, and 50.89% were ER-/PR-. ER-/PR+ status was seen in none of our cases. Correlation of ER and PR with HER 2 was possible in 90 cases and triple negative breast cancer (TNBC) status was observed in 32.2% of cases.Conclusions: Demography and ER positivity and incidence of TNBC is not different from rest of India, however the clinical utility for evaluation of PR receptor is to be further investigated.

show abstract

Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience

Cited by 44 publications

References 27 publications

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients

Clinico-Pathological Study: 48 Cases of Carcinoma Breast at Tertiary Care Centre in Rural Area

Study of correlation of ER, PR, HER2 receptor status in breast cancer at a single tertiary care hospital with emphasis on clinical utility of PR receptor

Contact Info

Product

Resources

About